STOCKS TELEGRAPH

Tag: TPST stock

  • After-Hour Session Sees Tempest Therapeutics (TPST) Shares Soar

    After-Hour Session Sees Tempest Therapeutics (TPST) Shares Soar

    Tempest Therapeutics, Inc. (NASDAQ: TPST) had a 48.58% increase in share price last Friday after hours, closing at $12.25. TPST shares surged when the European Medicines Agency (EMA) announced that the company’s investigational medication, amezalpat (TPST-1120), had been granted Orphan Drug Designation (ODD).

    Movement Gains Strength in the US and Europe

    This further classification from the EMA has already been backed by the U.S. Food and Drug Administration (FDA), which has already given amezalpat both Orphan Drug and Fast Track status.

    TPST-1120 can be used to treat hepatocellular carcinoma (HCC), a kind of liver cancer. Amezealpat is an oral selective PPAR⍺ antagonist that targets tumor cells and modifies immune responses.

    Tempest Therapeutics’ believe in amezalpat’s therapeutic potential is strengthened by these regulatory recognitions, which also highlight the significant unmet medical need in liver cancer.

    Clinical Data Emphasizes the Advantage of Survival

    The designations resulted from positive results from a global, randomized Phase 1b/2 clinical study that compared amezalpat with standard therapies—atezolizumab and bevacizumab—versus the standard treatment alone.

    Patients receiving the amezalpat regimen demonstrated a six-month extension in median overall survival, with a hazard ratio of 0.65. Importantly, the therapy also showed consistent benefit in patients with PD-L1 negative disease, supporting its dual mechanism of action.

    Expanded Research and Strategic Plans

    Further validation of amezalpat’s immune-modulatory effects was presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, underscoring its potential as an innovative cancer therapy.

    Additionally, the FDA has issued a “Study May Proceed” letter for a Phase 2 trial involving amezalpat for familial adenomatous polyposis (FAP), led by CP-CTNet and funded by the National Cancer Institute. The research is scheduled to start in 2025.

    As part of its efforts to streamline operations and increase shareholder value, Tempest Therapeutics (TPST) also confirmed a headcount reduction that was finished on April 30, 2025, and announced a strategic evaluation of its clinical-stage initiatives to complement its expanding portfolio.

  • Tempest Therapeutics, Inc. (TPST) Stock Skyrocketing as Meme Stock Phenomenon Continues to Spread Like Wildfire

    Tempest Therapeutics, Inc. (TPST) Stock Skyrocketing as Meme Stock Phenomenon Continues to Spread Like Wildfire

    Tempest Therapeutics, Inc. (TPST) stock prices skyrocketed by 98.18% shortly after market trading commenced on July 12th, 2021, bringing the price per share up to USD$31.05 early on in the trading day.

    W.B. 2021 Biotech Conference

    July 9th, 2021 saw the company announce that the Chief Medical Officer of the company, Sam Whiting, M.D., Ph.D., will be participating in a webcast panel at the William Blair 2021 Biotech Focus Conference. Titled “Developing Therapies for the Next Immuno-Oncology Targets” and will be held on July 14th, 2021. The announcement was met very positively by investors, who are hoping for a major announcement at the event.

    Rock Springs’ Stake in TPST

    Further driving the stock price higher is a recent SECSchedule 13-G filing that revealed Rock Springs Capital Management LP owned a 9.68% ownership stake in the company, having 642,155 shares under its control. The investment company is based in Baltimore and provides advisory services for businesses and institutional clients in regard to their security portfolios and portfolio management.

    Explaining TPST’s Meteoric Rise

    Nevertheless, the company’s recent stock price activity does not seem to be adequately contextualized by these developments. With the stock having risen as suddenly as it has, in the absence of concrete developments or changes in fundamentals, it seems likely that TPST has been selected as the latest target as a meme stock in the proliferation of the meme stock phenomenon that has been dominating the stock markets as of the start of the trading week.

    Meme Stock Phenomenon

    Driven by retail investors, underdog companies, sometimes on the brink of collapse, are artificially pumped with intentional disregard for any rational basis for the pump. Usually indicating a high short interest, these companies are selected as a means to take advantage of institutional investors’ confidence in the company’s stock prices falling. The coordinated short squeeze by retail investors has confounded Wall Street and has even resulted in the claiming of bankruptcy by some of the biggest names in finance.

    Future Outlook for TPST

    Rife with inherent risk and volatility, the recent fortuitous gains are not something that TPST can rely on to continue. Nevertheless, the increased exposure and skyrocketing of equity value afford the company opportunities to capitalize on in order to facilitate more organic increases in shareholder value.